Enanta Pharmaceuticals (NASDAQ:ENTA) Shares Pass Below Two Hundred Day Moving Average – Here’s Why

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)’s stock price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $13.47 and traded as low as $13.43. Enanta Pharmaceuticals shares last traded at $13.50, with a volume of 158,195 shares changing hands.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, June 23rd. Wall Street Zen downgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 22nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Friday, July 17th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $19.50.

Enanta Pharmaceuticals Price Performance

The company has a fifty day simple moving average of $13.49 and a two-hundred day simple moving average of $13.46. The company has a market capitalization of $369.82 million, a P/E ratio of -5.27 and a beta of 0.93.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). Enanta Pharmaceuticals had a negative net margin of 96.89% and a negative return on equity of 61.84%. The company had revenue of $14.36 million for the quarter, compared to analyst estimates of $16.76 million. Equities analysts anticipate that Enanta Pharmaceuticals, Inc. will post -2.36 earnings per share for the current year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC lifted its stake in shares of Enanta Pharmaceuticals by 1.5% in the first quarter. Janus Henderson Group PLC now owns 3,784,055 shares of the biotechnology company’s stock worth $47,717,000 after buying an additional 54,396 shares during the last quarter. Jupiter Topco LLC bought a new stake in shares of Enanta Pharmaceuticals during the 2nd quarter worth $53,252,000. BlackRock Inc. acquired a new position in Enanta Pharmaceuticals in the 2nd quarter valued at $47,304,000. Farallon Capital Management LLC grew its stake in Enanta Pharmaceuticals by 30.6% in the 4th quarter. Farallon Capital Management LLC now owns 2,772,262 shares of the biotechnology company’s stock valued at $43,719,000 after buying an additional 650,000 shares during the last quarter. Finally, Krensavage Asset Management LLC raised its holdings in Enanta Pharmaceuticals by 30.8% in the 4th quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company’s stock worth $43,626,000 after acquiring an additional 651,946 shares during the period. Institutional investors and hedge funds own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.